A pilot study that compared daily Biktarvy to three reduced dosing strategies, including to as low as once-weekly dosing, generated a lot of discussions at CROI 2025.
Even though the rationale for the study referenced the potency and long half-lives of bictegravir, emtricitabine and TAF to support less than daily dosing, the results were controversial as the lowest doses resulted in sub-optimal drug levels when viral failure would commonly be expected.
However, the results are also very timely though if less frequent dosing is shown to be safe in other settings, given the current uncertainty over continued funding for PEPFAR.
Read the full news story at HIV i-Base.
View all HIV i-Base reports from CROI 2025
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.